Jittiwutikan, JSrisurapanont, MJarusuraisin, N2009-05-272009-05-271997-09-05Jittiwutikan J, Srisurapanont M, Jarusuraisin N. Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. Journal of the Medical Association of Thailand. 1997 Sep; 80(9): 587-92http://imsear.searo.who.int/handle/123456789/40138Chotmaihet Thangphaet.Temporary inability to function without amphetamine and the experience of withdrawal syndrome enhance the tendency for repetitive use. The investigators proposed to examine the therapeutic effects of amineptine, an antidepressant with dopamine reuptake inhibition effect, for the treatment of amphetamine withdrawal. The 14-day study was carried out on a randomised, double-blind, placebo-controlled design. The authors assessed the severity of amphetamine withdrawal syndrome by using two measures and performed both end-point and intent-to-treat analyses. The results showed that amineptine helped relieve a depressed mood within one week and improved the general condition within 2 weeks. In conclusion, amineptine is effective in rapid relief of depressed mood and improves the general condition of patients with amphetamine withdrawal. Since the amphetamine withdrawal may last for several weeks, studies with longer duration should be conducted before incorporating amineptine into the clinical practice a of amphetamine withdrawal treatment.engAdolescentAdultAmphetamine-Related Disorders --drug therapyAntidepressive Agents, Second-Generation --therapeutic useDepression --drug therapyDibenzocycloheptenes --therapeutic useDopamine Uptake Inhibitors --therapeutic useDouble-Blind MethodFemaleHumansMaleProspective StudiesSubstance Withdrawal Syndrome --drug therapyTreatment OutcomeClinical Trial